Clinical trial
A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
NCT05668013 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 11, 2023
- Completion date
- January 31, 2027
- Enrollment
- 247 (actual)
- Sites
- 93
Conditions
As the registry lists them; a condition with its own page is linked.